Komorbide psychische Störungen bei Schizophrenie

Die große Bedeutung der Therapie komorbider psychischer Erkrankungen für Krankheitsverlauf und Behandlungskosten, die Gefahr eines Rückfalls, die Morbidität und Mortalität der Patienten und ihre Lebensqualität ermahnen dazu, psychische Komorbiditäten nicht unentdeckt und untherapiert zu lassen. Das gilt auch im umgekehrten Fall, wenn das Auftreten einer nicht-psychotischen Erkrankung vor Erstmanifestation der Schizophrenie die Diagnose und Behandlung der Psychose verzögert und so ebenfalls zu einem schlechteren Krankheitsverlauf und Outcome beiträgt. Die Abklärung von Komorbiditäten sowie geeignete pharmako-, psycho- und soziotherapeutische Maßnahmen sollten daher routinemäßig in das Behandlungskonzept der Schizophrenie integriert werden.

Comorbid mental disorders have significant detrimental effects on the course of schizophrenia, leading to higher treatment costs, higher risk of relapse, significantly higher morbidity and mortality and lower quality of life. Due to diagnostic difficulties, comorbidities can be overlooked and remain untreated because they are seen as part of the psychotic syndrome. On the other hand, patients often are treated exclusively because of their comorbidities, and the unspecific prodromal phase of a psychotic illness remains undetected. These facts emphasize the enormous importance of diagnosis and treatment of psychiatric comorbidities for clinical day-to-day practice. The detection of comorbidities and the administration of appropriate pharmacotherapeutic, psychotherapeutic and sociotherapeutic measures should therefore be an integral component of the routine treatment concept for schizophrenia.

Literatur

• 1 Addington D, Addington J. et al. . A depression rating scale for schizophrenics.  Schizophr Res. 1990;  3 247-51
• 2 Adler LE, Griffith JM. Concurrent medical illness in the schizophrenic patient. Epidemiology, diagnosis, and management.  Schizophr Res. 1991;  4 91-107
• 3 Arndt S, Tyrrell G. et al. . Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment.  Psychol Med. 1992;  22 379-88
• 4 Baynes D, Mulholland C. et al. . Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment.  Schizophr Res. 2000;  45 47-56
• 5 Bechdolf A, Pohlmann B. et al. . Motivational interviewing for patients with comorbid schizophrenia and substance abuse disorders: a review.  Fortschr Neurol Psychiatr. 2005;  73 728-35
• 6 Bersani G, Orlandi V. et al. . Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes.  Eur Arch Psychiatry Clin Neurosci. 2002;  252 86-92
• 7 Blanchard JJ, Brown SA. et al. . Substance use disorders in schizophrenia: review, integration, and a proposed model.  Clin Psychol Rev. 2000;  20 207-34
• 8 Braga RJ, Petrides G. et al. . Anxiety disorders in schizophrenia.  Compr Psychiatry. 2004;  45 460-8
• 9 Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care.  Am J Public Health. 1996;  86 973-7
• 10 Dixon L, Postrado L. et al. . The association of medical comorbidity in schizophrenia with poor physical and mental health.  J Nerv Ment Dis. 1999;  187 496-502
• 11 Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia.  Am J Psychiatry. 1986;  143 437-41
• 12 Gaebel W, Falkai P. Behandlungsleitlinie Schizophrenie. Darmstadt, Steinkopff 2005
• 13 Gearon JS, Kaltman SI. et al. . Traumatic life events and PTSD among women with substance use disorders and schizophrenia.  Psychiatr Serv. 2003;  54 523-8
• 14 Goldman LS. Medical illness in patients with schizophrenia.  J Clin Psychiatry. 1999;  60 10-5
• 15 Goodman WK, Price LH. et al. . The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.  Arch Gen Psychiatry. 1989;  46 1006-11
• 16 Goodwin RD, Amador XF. et al. . Anxiety and substance use comorbidity among inpatients with schizophrenia.  Schizophr Res. 2003;  61 89-95
• 17 Gouzoulis-Mayfrank E. Dual diagnosis of psychosis and addiction. From principles to practice.  Nervenarzt. 2004;  75 642-50
• 18 Green AI, Canuso CM. et al. . Detection and management of comorbidity in patients with schizophrenia.  Psychiatr Clin North Am. 2003;  26 115-39
• 19 Hamilton MC, Guy W. Hamilton depression scale [HAMD], in ECDEU assessment manual for psychopharmacology. Edited by U.S. National Institute of Health PRB. Rockville, MD 1967: 179-92
• 20 Harrow M, Yonan CA. et al. . Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?.  Schizophr Bull. 1994;  20 327-38
• 21 Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review.  Acta Psychiatr Scand. 2002;  106 83-96
• 22 Hawton K, Sutton L. et al. . Schizophrenia and suicide: systematic review of risk factors.  Br J Psychiatry. 2005;  187 9-20
• 23 Heila H, Isometsa ET. et al. . Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia.  Am J Psychiatry. 1997;  154 1235-42
• 24 Helmchen H, Hippius H. Depression syndrome in the course of neuroleptic therapy.  Nervenarzt. 1967;  38 455-8
• 25 House A, Bostock J. et al. . Depressive syndromes in the year following onset of a first schizophrenic illness*.  Br J Psychiatry. 1987;  151 773-9
• 26 Hughes JR, Hatsukami DK. et al. . Prevalence of smoking among psychiatric outpatients.  Am J Psychiatry. 1986;  143 993-7
• 27 Hwang MY, Morgan JE. et al. . Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study.  J Neuropsychiatry Clin Neurosci. 2000;  12 91-4
• 28 Keshavan MS, Duggal HS. et al. . Personality dimensions in first-episode psychoses.  Am J Psychiatry. 2005;  162 102-9
• 29 Kessler RC, Stang P. et al. . Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey.  Psychol Med. 1999;  29 555-67
• 30 Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence.  Am J Psychiatry. 1985;  142 1259-64
• 31 Kim-Cohen J, Caspi A. et al. . Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort.  Arch Gen Psychiatry. 2003;  60 709-17
• 32 Kingsbury SJ, Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia.  Hosp Community Psychiatry. 1990;  41 133-4
• 33 Knights A, Hirsch SR. „Revealed” Depression and drug treatment for schizophrenia.  Arch Gen Psychiatry. 1981;  38 806-11
• 34 Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia.  Am J Psychiatry. 1994;  151 1714-5
• 35 Koreen AR, Siris SG. et al. . Depression in first-episode schizophrenia.  Am J Psychiatry. 1993;  150 1643-8
• 36 Kovasznay B, Fleischer J. et al. . Substance use disorder and the early course of illness in schizophrenia and affective psychosis.  Schizophr Bull. 1997;  41 195-201
• 37 Lambert M, Conus P. et al. . The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.  Acta Psychiatr Scand. 2005;  112 141-8
• 38 Lambert M, Haasen C. et al. . Consumption patterns and motivation for use of addictive drugs in schizophrenic patients.  Psychiatr Prax. 1997;  24 185-9
• 39 Lonnqvist JK, Henriksson MM. et al. . Mental disorders and suicide prevention.  Psychiatry Clin Neurosci. 1995;  49 111-6
• 40 Mandel MR, Severe JB. et al. . Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.  Arch Gen Psychiatry. 1982;  39 197-203
• 41 Martin RL, Cloninger CR. et al. . Frequency and differential diagnosis of depressive syndromes in schizophrenia.  J Clin Psychiatry. 1985;  46 9-13
• 42 McDougle CJ, Epperson CN. et al. . A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.  Arch Gen Psychiatry. 2000;  57 794-801
• 43 McGlashan TH, Carpenter Jr. WT. Postpsychotic depression in schizophrenia.  Arch Gen Psychiatry. 1976;  33 231-9
• 44 McGorry PD, Chanen A. et al. . Posttraumatic stress disorder following recent-onset psychosis. An unrecognized postpsychotic syndrome.  J Nerv Ment Dis. 1991;  179 253-8
• 45 Mendlowicz MV, Braga RJ. et al. . Comorbidity and disability in outpatients with schizophrenia.  Am J Psychiatry. 2005;  162 400-1
• 46 Moran P, Hodgins S. The correlates of comorbid antisocial personality disorder in schizophrenia.  Schizophr Bull. 2004;  30 791-802
• 47 Morrison D, Clark D. et al. . Worsening of obsessive-compulsive symptoms following treatment with olanzapine.  Am J Psychiatry. 1998;  155
• 48 Mueser KT, Drake RE. et al. . Dual diagnosis: a review of etiological theories.  Addict Behav. 1998;  23 717-34
• 49 Mueser KT, Yarnold PR. et al. . Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.  Schizophr Bull. 1990;  16 31-56
• 50 Muller JE, Koen L. et al. . Anxiety disorders and schizophrenia.  Curr Psychiatry Rep. 2004;  6 255-61
• 51 Naber D. Treatment of drug dependent patients in a general hospital.  Internist (Berl). 1994;  35 858-62
• 52 Nechmad A, Ratzoni G. et al. . Obsessive-compulsive disorder in adolescent schizophrenia patients.  Am J Psychiatry. 2003;  160 1002-4
• 53 Ongur D, Goff D. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status.  Schizophr Res. 2005;  75 349-62
• 54 Owen C, Rutherford V. et al. . Noncompliance in psychiatric aftercare.  Community Ment Health J. 1997;  33 25-34
• 55 Pallanti S, Quercioli L. et al. . Social anxiety in outpatients with schizophrenia: a relevant cause of disability.  Am J Psychiatry. 2004;  161 53-8
• 56 Perenyi A, Norman T. et al. . Negative symptoms, depression, and parkinsonian symptoms in chronic, hospitalised schizophrenic patients.  J Affect Disord. 1998;  48 163-9
• 57 Perkins D, Lieberman J. et al. . Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.  Br J Psychiatry. 2004;  185 18-24
• 58 Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.  Br J Psychiatry. 1995;  166 727-33
• 59 Poyurovsky M, Dorfman-Etrog P. et al. . Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.  Int Clin Psychopharmacol. 2000;  15 169-73
• 60 Poyurovsky M, Fuchs C. et al. . Obsessive-compulsive disorder in patients with first-episode schizophrenia.  Am J Psychiatry. 1999;  156 1998-2000
• 61 Read J, Agar K. et al. . Sexual and physical abuse during childhood and adulthood as predictors of hallucinations, delusions and thought disorder.  Psychol Psychother. 2003;  76 1-22
• 62 Read J, van Os J. et al. . Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications.  Acta Psychiatr Scand. 2005;  112 330-50
• 63 Regier DA, Farmer ME. et al. . Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.  Jama. 1990;  264 2511-8
• 64 Schafer I, Harfst T. et al. . Childhood trauma and dissociation in female patients with schizophrenia spectrum disorders: an exploratory study.  J Nerv Ment Dis. 2006;  194 135-8
• 65 Scheller-Gilkey G, Moynes K. et al. . Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse.  Schizophr Res. 2004;  69 167-74
• 66 Schimmelmann BG, Conus P. et al. . Diagnostic stability 18 months after treatment initiation for first-episode psychosis.  J Clin Psychiatry. 2005;  66 1239-46
• 67 Schonfeld WH, Verboncoeur CJ. et al. . The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder.  J Affect Disord. 1997;  43 105-19
• 68 Sevy S, Robinson DG. et al. . Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder.  Acta Psychiatr Scand. 2001;  104 367-74
• 69 Sim K, Mahendran R. et al. . Health-related quality of life and psychiatric comorbidity in first episode psychosis.  Compr Psychiatry. 2005;  46 278-83
• 70 Sim K, Swapna V. et al. . Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Program (EPIP) experience.  Acta Psychiatr Scand. 2004;  109 23-9
• 71 Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.  Schizophr Bull. 1991;  17 75-98
• 72 Siris SG, Addington D. et al. . Depression in schizophrenia: recognition and management in the USA.  Schizophr Res. 2001;  47 185-97
• 73 Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study.  Acta Psychiatr Scand. 1994;  90 247-51
• 74 Tollefson GD, Sanger TM. et al. . Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.  Arch Gen Psychiatry. 1998;  55 250-8
• 75 Wassink TH, Flaum M. et al. . Prevalence of depressive symptoms early in the course of schizophrenia.  Am J Psychiatry. 1999;  156 315-6

Korrespondenzadresse: